Considering the precarious situation Faron has found itself in, perhaps the possibility of merging it with Orion should be seriously explored. Although Orion might not yet be considered a true Big Pharma (BP) company, a merger with Faron would not be an overwhelming risk for it. Perhaps a couple of million B-shares would be needed for a share swap, which is only just under 1.5 percent of Orion’s share capital, so it would likely hardly weigh on the stock price. It might even raise it. Orion would get more, at least somewhat promising, new candidates for its research pipeline. The EU would probably take an encouraging view of such a solution, and it would also be an interesting step for the development of the Finnish pharmaceutical industry.
8 Likes